Hormones and thrombosis: risk across the reproductive years and beyond.


Journal

Translational research : the journal of laboratory and clinical medicine
ISSN: 1878-1810
Titre abrégé: Transl Res
Pays: United States
ID NLM: 101280339

Informations de publication

Date de publication:
11 2020
Historique:
received: 28 02 2020
revised: 18 06 2020
accepted: 24 06 2020
pubmed: 1 7 2020
medline: 21 10 2020
entrez: 30 6 2020
Statut: ppublish

Résumé

Endogenous and exogenous hormones have significant effects on coagulation and may tip the hemostatic balance toward thrombosis. The endogenous hormonal changes in pregnancy and polycystic ovary syndrome, and exogenous hormonal contraception, menopause replacement, and transgender cross-hormone replacement may increase thromboembolism risk. Using the lowest effective dose is critical for prevention, but once thrombosis occurs, anticoagulation may be required, in some, long term. We review the relative risk of thrombosis in these conditions, risk factors, and anticoagulation treatment and prevention. Implementation of lowest effective hormonal therapies, thrombosis reduction strategies, and current anticoagulation management are critical for optimal patient outcomes.

Identifiants

pubmed: 32599096
pii: S1931-5244(20)30150-X
doi: 10.1016/j.trsl.2020.06.011
pii:
doi:

Substances chimiques

Hormones 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

9-19

Subventions

Organisme : NCRR NIH HHS
ID : UL1 RR024153
Pays : United States
Organisme : NCRR NIH HHS
ID : M01 RR000056
Pays : United States
Organisme : NHLBI NIH HHS
ID : R34 HL105870
Pays : United States
Organisme : NHLBI NIH HHS
ID : T35 HL074708
Pays : United States
Organisme : NHLBI NIH HHS
ID : U34 HL114674
Pays : United States
Organisme : NHLBI NIH HHS
ID : U34 HL119582
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL068429
Pays : United States
Organisme : NHLBI NIH HHS
ID : K12 HL087064
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL133815
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000005
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL112614
Pays : United States
Organisme : NCRR NIH HHS
ID : TL1 RR024155
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL061937
Pays : United States
Organisme : NHLBI NIH HHS
ID : P01 HL081588
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Nicoletta Machin (N)

Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania.

Margaret V Ragni (MV)

Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania. Electronic address: ragni@pitt.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH